-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – MP-0317 in Ovarian Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - MP-0317 in Ovarian Cancer report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data.MP-0317 in Ovarian Cancer Drug Details:MP-0317 is under development for the treatment of...
-
Sector Analysis
Heart Failure in Major Markets, Disease Management, Epidemiology, Pipeline Assessment, Unmet Needs and Drug Forecast to 2032
Heart Failure Major Market Overview The heart failure market size across the 7MM was valued at $31.9 billion in 2022 and will achieve a CAGR of more than 5% during 2022-2032. The launch of five oral agents and label extensions of SGLT2 inhibitors will fuel the heart failure market growth during the forecast period. Heart Failure Market Outlook, 2022-2032 ($ Billion) Buy Full Report to Know More About the Heart Failure Market Forecast Download a Free Report Sample The HF...
-
Company Profile
BioCardia Inc – Company Profile
BioCardia Inc (BioCardia) is a regenerative medicine company. It develops novel therapeutics for cardiovascular diseases. The company develops biotherapeutic candidates that include a CardiAMP cell therapy system, autologous minimally processed bone marrow cells and an allogeneic off-the-shelf mesenchymal stem a cell product candidate for ischemic systolic heart failure. BioCardia's CardiAMP cell therapy system comprises a cell potency screening test, a point-of-care cell processing platform, and a biotherapeutic delivery system. The company sells its products through a network of distributors across...
Add to Basket -
Product Insights
Cardiac Catheters – BioCardia Inc – MORPH
GlobalData, the industry analysis specialist, has released its latest report: Cardiac Catheters - BioCardia Inc - MORPH. The selling price or list price of a medical device is driven by numerous factors, such as therapy area and complexity of procedure, level of reimbursement, development costs, the number of competing manufacturers, product life cycle, and whether there have been any recent new technology or product launches. In addition, the final selling pricing of medical devices is also impacted by the discounting...
-
Product Insights
Introducer Sheaths – BioCardia Inc – MORPH
GlobalData, the industry analysis specialist, has released its latest report: Introducer Sheaths - BioCardia Inc - MORPH. The selling price or list price of a medical device is driven by numerous factors, such as therapy area and complexity of procedure, level of reimbursement, development costs, the number of competing manufacturers, product life cycle, and whether there have been any recent new technology or product launches. In addition, the final selling pricing of medical devices is also impacted by the discounting...
-
Product Insights
Net Present Value Model: CardiAMP
Overview Evaluating the value of drugs is a complicated practice and requires a deep knowledge of the drug itself, the market currently and in the future, knowledge of cash inflows and outflows and the potential success rates for each stage of drug development. GlobalData has done all of this work for you, leveraging its gold standard Drugs Intelligence database to create high-value NPV models for purchase on a drug-by-drug basis. Drug Operating Profit Model CardiAMP Drug Details CardiAMP is under...
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – CardiAMP
Overview How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data to allow you to track and predict specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using a combination of machine learning and proprietary models. Likelihood of Approval (LoA) - Industry CardiAMP Drug Details CardiAMP is under development for the treatment of chronic myocardial ischemia...
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – CardiALLO
Overview How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data to allow you to track and predict specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using a combination of machine learning and proprietary models. Likelihood of Approval (LoA) - Industry CardiALLO Drug Details CardiALLO is under development for the treatment of ischemic systolic heart...
-
Report Bundle
56% offTrends in Medical Devices – Report Bundle (7 Reports)
A rise in disease awareness, improved accessibility to personalized medicine, and technological advancements are transforming the medical device industry. It is helping patients to avoid potential adverse events and reducing unnecessary hospitalizations and outpatient costs. The field has expanded from a handful of drug manufacturers to include many high-end manufacturers. Accessing the in-depth insight from the Trends in Medical Devices bundle can help you: Make informed decisions about investments, partnerships, and product development Understand your competitors’ strengths and weaknesses, identify areas...
-
Product Insights
Myocardial Ischemia Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
Myocardial ischemia pipeline market research report provides comprehensive information on the therapeutics under development for Myocardial Ischemia, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Myocardial Ischemia and features dormant and...